Kenvue declares quarterly cash dividend of $0.21 per share
Payment is due October 2, 2026, for shareholders recorded by September 21, 2026.
See the latest news and media coverage for Kenvue. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global consumer health company
kenvue.comLast updated
In short: Kenvue faced ongoing litigation over Tylenol while progressing toward a $48.7 billion acquisition by Kimberly-Clark and reporting growth.
Payment is due October 2, 2026, for shareholders recorded by September 21, 2026.
This first OTC fixed-dose combo of acetaminophen and naproxen sodium offers new opioid-free pain relief option
Net sales rose 3.0% with diluted EPS up 9% to $0.24 amid pending Kimberly-Clark merger approval and FDA acceptance of new Tylenol.
The company's Healthy Lives Mission Report shows progress in emissions reduction and renewable energy.
The maker of Tylenol and a group of retailers and pharmacy operators asked a federal appeals court t...
Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40...
Kenvue, which owns the Tylenol brand name product, in an emailed statement advised pregnant or breastfeeding women to check with a health professional before using...
Kenvue slides 3.18% today to $17.81 amid seller pressure and regulatory review of the $40B Kimberly-Clark bid, maintaining ...
Track Kenvue and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kenvue and other trending companies.